<DOC>
	<DOCNO>NCT02450513</DOCNO>
	<brief_summary>Observational pharmacokinetics study adalimumab patient active refractory Crohn 's disease naïve TNF antagonist therapy .</brief_summary>
	<brief_title>Adalimumab Trough Concentrations Crohn 's Disease : A Pilot Pharmacokinetic Study</brief_title>
	<detailed_description>Adalimumab ( ADM ) , fully human tumor necrosis factor ( TNF ) antagonist , effective treating patient Crohn 's disease ( CD ) . A correlation concentration effect observe distinct time point . The aim evaluate correlation early longitudinal measurement ADM different biological marker disease activity induction maintenance clinical remission . This prospective two-center open-label observational study anti-TNF naïve patient moderate severe CD induce ADM 160/80 mg week 0 2 40 mg every 2 week monotherapy . All patient need TNF antagonist therapy fulfill standard reimbursement criterion ( Belgium ) . Serum sample take pre post first injection week 1 , 2 , 3 , 4 , 12 , 26 52 . Following parameter determine : C-reactive protein , albumin , TNF , ADM , antibodies ADM , hemoglobin , platelet count leukocyte count . Clinical response remission evaluate use Harvey-Bradshaw index .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Patients confirm diagnosis Crohn 's disease , fulfil criterion reimbursement ( Belgium ) . Patients active disease define HarveyBradshaw index &gt; 4 and/or Creactive protein concentration &gt; 5 mg/l . Informed consent . Patients ulcerative colitis . Patients treat placebo control trial . Patients unwilling participate withdrawing inform consent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adalimumab</keyword>
	<keyword>anti-TNF</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>trough level</keyword>
	<keyword>immunogenicity</keyword>
</DOC>